NeoGenomics Inc (NAS:NEO)
$ 13.01 0 (0%) Market Cap: 1.66 Bil Enterprise Value: 1.88 Bil PE Ratio: 0 PB Ratio: 1.79 GF Score: 78/100

Q1 2021 Neogenomics Inc Earnings and to Discuss Acquisition of Inivata Ltd Call Transcript

May 05, 2021 / 12:30PM GMT
Release Date Price: $41.95 (-11.81%)
Operator

Good morning, ladies and gentlemen, and welcome to the NeoGenomics First Quarter 2021 Earnings Call. (Operator Instructions) It is now my pleasure to turn the floor over to your host, Doug VanOort. Sir, the floor is yours.

Douglas M. VanOort
NeoGenomics Laboratories, Inc. - Executive Chairman and CEO

Well, thank you, Holly, and good morning, everyone. I'd like to welcome everyone to NeoGenomics' First Quarter 2021 Conference Call. We have a lot of exciting news to share today, but first, let me introduce my fellow team members on the call.

Joining me this morning from our Fort Myers headquarters are Mark Mallon, our new Chief Executive Officer; Kathryn McKenzie, our Chief Financial Officer; George Cardoza, President of our Pharma Services Division; Bill Bonello, President of our Informatics Division; Doug Brown, our Chief Strategy and Corporate Development Officer; and Charlie Eidson, our Manager of Investor Relations. Also joining us this morning via phone from the United Kingdom is Inivata CEO, Dr. Clive Morris.

Before we begin our

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot